Latest News

Dimerix (ASX:DXB) has announced that the US FDA has given conditional approval for the brand name QYTOVRA for its Phase 3 clinical drug candidate.

The 2022-23 Final Budget Outcome has revealed that spending on the pharmaceutical services and benefits sub-function was $1 billion lower than expected in May but still 14 per cent higher than last year.

Processes like the HTA review represent the hijacking of public health by officials and a small group of privileged stakeholders who then use the instruments of government to impose an all-pervasive conformity that punishes dissent by exclusion.

The Society of Hospital Pharmacists of Australia has announced a new recognition program that aims to transform pharmacy practice in Australia and New Zealand.

A special guest joins the podcast to discuss the lost opportunity to celebrate a significant anniversary for the PBS and even reshape perceptions of the program. The government has also released its Final Budget Outcome, revealing strong growth in pharmaceutical spending and a problem with invoicing companies for rebates.

Pharmac has featured again during New Zealand's election campaign with the future of its potential fiscal 'cliff' the focus of debate.

The company said the 'Welcome to the mRNAge' campaign will include a range of assets that aim to create an approachable and inclusive connection with the audience, to expand the understanding of the possibilities of mRNA technology.

This matters because so many people responsible for decisions during the pandemic are beyond the powers of this inquiry, such as those responsible for major decisions on COVID-19 vaccines, including retired health minister Greg Hunt, former health department secretary Professor Brendan Murphy AC, and ex-TGA head John Skerritt.

AuBiotech CEO Lorraine Chiroiu has announced that she will depart the organisation in December after five years leading the peak representative body for Australia's biotechnology sector.

Two US congressmen, one Republican and the other a Democrat, have moved to amend the Biden administration’s Inflation Reduction Act with the goal of protecting investment in new therapies for rare diseases.

The Department of Health and Aged Care has re-published a communique released by the UK's National Institute for Health and Care Excellence last month on the international health technology assessment collaboration.